The National Institutes of Health (NIH) has awarded EpiVax with a Small Business Innovation Research (SBIR) grant of $324,980. The company is going to use the funding to further develop its Personalized Immunogenicity Assessment (PIMA) tool, designed to assess risk of enzyme replacement therapy failure in patients with…
treatment
Duke Health researchers are planning to launch a Phase 1 trial to test the safety of a new investigational gene therapy they developed to treat patients with Pompe disease. They are currently screening (NCT03285126) adults with late-onset Pompe disease to select eligible participants for the upcoming trial.
The biotech companies Shire and NanoMedSyn have launched a new research partnership to evaluate a potential treatment for lysosomal storage disorders including Pompe disease. NanoMedSyn has developed an enzyme replacement therapy using proprietary technology called AMFA that was shown in preclinical models to have promising biological activity.
Recent Posts
- Immune changes seen in late-onset Pompe may affect treatment response
- Some decisions don’t feel like choices in our Pompe disease journey
- LOPD patients face long delays in diagnosis, gaps in healthcare: Survey
- The joy of unexpected connections with other families who ‘get it’
- Newborn screening for Pompe disease helps avoid years of treatment delay